Published in Pain and Central Nervous System Week, August 29th, 2005
The drug candidate was safe and well tolerated after intravenous infusion, and resulted in plasma levels of CR665 expected to be associated with clinical analgesic activity. In addition, CR665 infusion triggered a quantitative endocrine biomarker of peripheral kappa opioid receptor activation in both men and women.
The phase Ia single-center clinical trial evaluated the safety, tolerability, pharmacokinetic profile, and pharmacological activity of CR665 in a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain and Central Nervous System Week